Search
Genelux Corp
GNLXAdd to Watchlist
2.470USD
-0.045-1.79%
Market hours 09/24, 12:32（ET）
110.75MMarket Cap
LossP/E TTM
About Genelux Corp Company
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Genelux Corp Profile
Ticker SymbolGNLX
Company nameGenelux Corp
IPO dateJan 26, 2023
CEOZindrick (Thomas)
Number of employees24
Security typeOrdinary Share
Fiscal year-endJan 26
Address2625 Townsgate Road, Suite 230
CityWESTLAKE VILLAGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code91361
Phone18052679889
Websitehttps://genelux.com/
Ticker SymbolGNLX
IPO dateJan 26, 2023
CEOZindrick (Thomas)
Company Executives of Genelux Corp
Name
Name/Position
Position
Shareholding
Change
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
Dr. Joseph Cappello, Ph.D.
Dr. Joseph Cappello, Ph.D.
Chief Technical Officer
Chief Technical Officer
194.67K
-5.60%
Dr. Joseph Cappello, Ph.D.
Dr. Joseph Cappello, Ph.D.
Chief Technical Officer
Chief Technical Officer
194.67K
-5.60%
Dr. Joseph Cappello, Ph.D.
Dr. Joseph Cappello, Ph.D.
Chief Technical Officer
Chief Technical Officer
194.67K
-5.60%
Ms. Mary Mirabelli
Ms. Mary Mirabelli
Independent Director
Independent Director
80.41K
+35.33%
View more
Name
Name/Position
Position
Shareholding
Change
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Dr. John Thomas, Ph.D.
Dr. John Thomas, Ph.D.
Independent Director
Independent Director
478.91K
+3.84%
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
Mr. Eric Groen, J.D.
Mr. Eric Groen, J.D.
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
General Counsel, Corporate Secretary, Chief Compliance Officer, Head of Business Development
233.96K
--
FAQs
Who are the top five shareholders of Genelux Corp?
The top five shareholders of Genelux Corp are: Dr. John Thomas, Ph.D.
How many institutions hold shares of Genelux Corp (GNLX)?
As of 2026Q1, 186 institutions hold shares of Genelux Corp, with a combined market value of approximately 13.88M, accounting for 30.96% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 3967281.00.